For more information please contact:
Head of Healthcare Investment Banking
Michael Margolis, R.Ph.
Warren Dunnavant II
Head of Equity
Senior Vice President
On February 18th, ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) closed an underwritten public offering of an aggregate of 26,650,000 shares of its common stock at a price of $0.60 per share, and warrants to purchase up to an aggregate of 18,655,000 shares of its common stock. The net offering proceeds to ImmunoCellular from this offering were approximately $14.6 million.
ImmunoCellular intends to use the net proceeds of this offering to enroll its current planned phase III clinical trial of ICT-107, to complete phase I development of ICT-121, to commence its T-cell research program, and for working capital and general corporate purposes. A portion of the net proceeds may be used to acquire additional technologies.
ROTH Capital Partners acted as sole book-running manager for the offering.
About ImmunoCellular Therapeutics
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular's lead program is ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma, for which a phase III registration program is being planned. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell vaccine targeting CD133; ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer killing T-cells. (Source: Company Press Release: 2/15/2015)
About ROTH Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. and Hong Kong. For more information on ROTH, please visit